JAMA Network
About The Study: Among patients with commercial insurance, manufacturer-sponsored coupon use declined substantially between 2017 and 2024, whereas per-claim coupon amounts increased. These patterns may reflect several mechanisms. Manufacturers may be concentrating coupon programs on fewer products or for fewer patients while offering larger incentives in response to formulary pressures or expanded copay accumulator programs. Greater coupon amounts may also reflect higher underlying patient cost-sharing requirements.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
